Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus

The antiviral neuraminidase inhibitor oseltamivir (OSV) is widely used to suppress viral replication in the treatment of influenza. Here, we report that OSV administration significantly suppressed respiratory mucosal secretory IgA responses with respect to antigen (Ag)-specific antibody (Ab) product...

Full description

Saved in:
Bibliographic Details
Published in:Microbes and infection 2010-09, Vol.12 (10), p.778-783
Main Authors: Takahashi, Etsuhisa, Kataoka, Kosuke, Fujii, Kazuyuki, Chida, Junji, Mizuno, Dai, Fukui, Makoto, Hiro-O Ito, Fujihashi, Kohtaro, Kido, Hiroshi
Format: Article
Language:English
Subjects:
Animals
Antibodies, Viral - immunology
Antiviral Agents - administration & dosage
Antiviral Agents - adverse effects
Biological and medical sciences
Female
Fundamental and applied biological sciences. Psychology
Immunity, Mucosal - drug effects
Immunoglobulin A
Immunoglobulin A - immunology
Immunoglobulin G - immunology
Immunosuppression
Immunosuppressive Agents - administration & dosage
Influenza A virus - immunology
Influenza A virus infection
Mice
Mice, Inbred BALB C
Microbiology
Miscellaneous
Mucosal immunity
Orthomyxoviridae Infections - drug therapy
Orthomyxoviridae Infections - immunology
Oseltamivir
Oseltamivir - administration & dosage
Oseltamivir - adverse effects
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The antiviral neuraminidase inhibitor oseltamivir (OSV) is widely used to suppress viral replication in the treatment of influenza. Here, we report that OSV administration significantly suppressed respiratory mucosal secretory IgA responses with respect to antigen (Ag)-specific antibody (Ab) production and also the induction of Ag-specific IgA Ab-forming cells, but not systemic IgG responses, in weanling mice as a model of pediatric influenza. Neutralizing activities of the airway fluids in oral OSV-treated mice were significantly less than those of sham-treated mice. Our findings suggest the risk of re-infection in patients showing a low mucosal response following OSV treatment.
ISSN:1286-4579
1769-714X
DOI:10.1016/j.micinf.2010.04.013